Recent Advances in Our Understanding of Insulin Action and Insulin Resistance
- Derek Le Roith, MD, PHD1 and
- Yehiel Zick, PHD2
- 1Clinical Endocrinology Branch, National Institutes of Health, Bethesda, Maryland
- 2Department of Biological Regulation, Weizmann Institute for Science, Rehovot, Israel
Abstract
Insulin signaling at the target tissue results in a large array of biological outcomes. These events are essential for normal growth and development and for normal homeostasis of glucose, fat, and protein metabolism. Elucidating the intracellular events after activation of the IR has been the primary focus of a large number of investigators for decades, and for excellent reasons. Understanding the signaling pathways involved in insulin action could lead to a better understanding of the pathophysiology of insulin resistance associated with obesity and type 2 diabetes, and identifying key molecules and processes could lead to newer and more effective therapeutic agents for treating these common disorders.
This review summarizes our previous understanding of how insulin acts and outlines some recent developments in our understanding of insulin action and insulin resistance at the cellular level, beginning with a discussion on the discovery of evolutionarily conserved molecules of the insulin signaling pathways. This article will also provide a summary of a few in vitro and cellular models of insulin resistance and a description of some new paradigms in the cellular mechanisms of insulin action.
This review will not attempt to be all-inclusive; for a more comprehensive understanding, readers are referred to more complete reviews on insulin action (1–5).
Footnotes
-
Address correspondence and reprint requests to Derek Le Roith, MD, Chief, Moll. Cell Endocrine Branch, Rm. 8D12, Bldg. 10, NIH MSC 1758, Bethesda, MD, 20892-1758. E-mail: derek{at}helix.nih.gov.
Received for publication 21 June 2000 and accepted in revised form 10 November 2000.
D.L.R. has been a paid lecturer for SCP Communications, which has received funding from SmithKline Beecham.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances














